Target Cancer Genomic Profiling Service

ACTDrug®+ : Select Drugs for Your Cancer Patient

Providing tailored drug options through precise genomic profiling for 35 druggable genes

A Precise Choice for Cancer Genomic Profiling

ACTDrug®+ is a next-generation sequencing based assay, sequencing 35 druggable genes simultaneously from cancer specimens in our ISO 17025 and CAP accredited lab. This assay is specially designed for patients with breast cancer, lung and colorectal cancer, providing tailored genomic profile and recommendations of targeted drugs approved by USFDA.

Exploring Various Genetic Alterations for More Precise Therapeutic Implications

ACTDrug®+ sequences 35 druggable genes and performs various genetic variation analysis. Besides single nucleotide variation (SNV) and small insertion/ deletion (InDel), it provides copy number variation (CNV) analysis to detect more drug related important alterations and provide more precise implications


Hallmark of ACTDrug®+

  1. Target Cancer Types

    Breast , Lung and Colorectal cancer
  2. Target Patients

    Newly diagnosed with breast cancer, lung and colorectal cancer.
    First time treated with targeted therapy
  3. Precise Report Content

    Genetic alterations.
    Therapeutic implications for FDA approved drugs

Why ACTDrug®+

Can be performed Fast and Accurately

  1. Drug Targeted-Based Panel

    Sequencing 35 druggable genes with genetic alterations
  2. Offering Tailored Drug Options

    Analyzing single nucleotide variation (SNV), small insertion/deletion (InDel) and copy number variation (CNV) to provide tailored drug options
  3. Short Turnaround Time

    Providing professional solutions within 14 calendar days
  4. High Sensitivity

    Using NGS platform for microscale specimens
  5. Pioneering Bioinformatics

    Specializing in cancer biology, medical biology, molecular biology, cell biology, immunology, bioinformatics, data science,and pharmaceutical biology to provide insightful interpretation


NGS Sequencing

35 Druggable Genes


> 2000

NGS Sequencing Mean Depth

> 1000 X

Additional Assay for Lung Cancer

fusion gene detection

( including 72 fusion transcripts )

Additional Assay for Colorectal & Gastric Cancer

Microsatellite instability (MSI) testing

Sample Types


Core needle biopsy

Frozen tissue

Pleural effusion *

Ascites samples *

Purified DNA

* Pleural effusion and ascites samples need to be processed into cell blocks before sending to ACT Genomics.